Spots Global Cancer Trial Database for A Safety Study of SGN-LIV1A in Breast Cancer Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Safety Study of SGN-LIV1A in Breast Cancer Patients
Official Title: A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
Study ID: NCT01969643
Study Description
Brief Summary: This study will examine the safety and tolerability of ladiratuzumab vedotin (LV) in patients with metastatic breast cancer. LV will be given alone or in combination with trastuzumab.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
Pinnacle Oncology Hematology, Scottsdale, Arizona, United States
UC San Diego / Moores Cancer Center, La Jolla, California, United States
Cedars Sinai Medical Center / Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
University of California at San Francisco, San Francisco, California, United States
UCLA Medical Center / David Geffen School of Medicine, Santa Monica, California, United States
Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States
Poudre Valley Health System (PVHS), Fort Collins, Colorado, United States
Yale Cancer Center, New Haven, Connecticut, United States
The Whittingham Cancer Center / Norwalk Hospital, Norwalk, Connecticut, United States
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Piedmont Cancer Institute, Atlanta, Georgia, United States
University of Chicago Medical Center, Chicago, Illinois, United States
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States
University of Maryland, Baltimore, Maryland, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States
Allina Health Cancer Institute, Minneapolis, Minnesota, United States
University of Minnesota, Minneapolis, Minnesota, United States
Mayo Clinic Rochester, Rochester, Minnesota, United States
Washington University in St Louis, Saint Louis, Missouri, United States
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
Columbia University Medical Center, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Weill Cornell Medicine, New York, New York, United States
Wake Forest Baptist Medical Center / Wake Forest University, Winston-Salem, North Carolina, United States
Case Western Reserve University / University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
The Cleveland Clinic, Cleveland, Ohio, United States
Oregon Health and Science University, Portland, Oregon, United States
Tennessee Oncology-Nashville/Sarah Cannon Research Institute, Nashville, Tennessee, United States
Texas Oncology - Baylor Sammons Cancer Center, Dallas, Texas, United States
Cancer Care Centers of South Texas - HOAST/Texas Oncology, New Braunfels, Texas, United States
Northwest Medical Specialties, Puyallup, Washington, United States
Swedish Cancer Institute, Seattle, Washington, United States
Seattle Cancer Care Alliance / University of Washington, Seattle, Washington, United States
West Virginia University, Morgantown, West Virginia, United States
Contact Details
Name: Brandon Croft, PharmD
Affiliation: Seagen Inc.
Role: STUDY_DIRECTOR
Name: Zejing Wang, MD, PhD
Affiliation: Seagen Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
